Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Peripheral Blood
100%
Filgrastim
100%
Blood Donors
100%
Plerixafor
100%
Engraftment
66%
Marrow
50%
Granulocyte Colony-stimulating Factor (G-CSF)
33%
Low Dose Rate
33%
Donor Site Morbidity
33%
Donor Source
33%
Phase II Trial
16%
Phase II Clinical Trial
16%
Natural Killer Cells
16%
Operating Room
16%
Clinical Considerations
16%
Biological Mechanisms
16%
American Society
16%
Marrow Transplantation
16%
Living Donor
16%
Peripheral Blood Progenitor Cells
16%
Unrelated Donor
16%
Graft Source
16%
Dendritic Cell Precursor
16%
Plasmacytoid Dendritic Cells
16%
Physician Utilization
16%
Medicine and Dentistry
Chronic Graft Versus Host Disease
100%
Cell Transplantation
100%
Filgrastim
100%
Engraftment
100%
Plerixafor
100%
Blood Donor
100%
Hematopoietic Cell
100%
Granulocyte Colony Stimulating Factor
50%
Clinical Trial
25%
Graft Versus Host Reaction
25%
Biological Product
25%
Precursor
25%
Operating Room
25%
Progenitor Cell
25%
Natural Killer Cell
25%
Plasmacytoid Dendritic Cell
25%
Phase III Trials
25%
Immunology and Microbiology
Chronic Graft Versus Host Disease
100%
Filgrastim
100%
Engraftment
100%
Hematopoietic Cell
100%
Plerixafor
100%
Cell Transplantation
100%
Granulocyte Colony-Stimulating Factor
50%
Myeloid
25%
Biological Product
25%
Graft-Versus-Host Disease
25%
Natural Killer Cell
25%
Precursor
25%
Gastrin Cell
25%
Plasmacytoid Dendritic Cell
25%